NCT06187883Completed
Pulsed Radiofrequency of Lateral Femoral Cutaneous Nerve
Does Obesity EffectThe Successful Response to the Pulsed Radiofrequency of Lateral Femoral Cutaneous Nerve in Meralgia Parestetica? : A Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 22 Apr 2024
Brief summary (registry, in English)
In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 6 Dec 2023
- Start date
- 21 Nov 2023
- Primary completion date
- 30 Nov 2023
- Lead sponsor
- Mersin Training and Research Hospital
- Diseases
- Obesity
- NCT number
- NCT06187883
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 21 Nov 2023 to the primary completion date, 30 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If a new analgesic drug was prescribed during the follow-up period that could affect the evaluation of outcomes, the patients were also excluded.
Other illness
- Patients with secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism), malignancy, pregnancy, skin infection in the inguinal region or dermatitis, lumbar radiculopathy, polyneuropathy, and cardiac pacemakers were excluded.
Other
- inadequate follow-up or missing documentation
- Patients who missed appointments, or were unable to communicate with; were not included in the study.
- In the SSEP analysis, when the latency of LFCN was not evaluated in both sides, these patients were not also included in the study.
Who the study is looking for
- older than 18 years treated with PRF neuromodulation of LFCN for MP
- followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Suna Aşkın Turan Coordinator of this site? Confirm its status | Mersin | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.